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Abstract Proteins containing a RhoGAP (Rho GTPase acti-
vating protein) domain usually function to catalyze the hydro-
lysis of GTP that is bound to Rho, Rac and/or Cdc42, inacti-
vating these regulators of the actin cytoskeleton. Using database
searches, at least 53 distinct RhoGAP domain-containing pro-
teins are likely to be encoded in human DNA. Phylogenetic
analysis of only the RhoGAP domains divides these proteins
into distinct families that appear to be functionally related.
We also review the current understanding of the structure and
likely functions of these human proteins. The presence of Rho-
GAP domains in a number of di¡erent human proteins suggests
that cytoskeletal changes, regulated by Rho GTPase, may be
integrated with many di¡erent signaling pathways. - 2002
Published by Elsevier Science B.V. on behalf of the Federation
of European Biochemical Societies.
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1. Introduction
The Rho family of GTPases have emerged as key players in
regulating a diverse set of biological activities including roles
in actin polymerization, focal complex and focal adhesion
assembly, cell cycle progression, membrane tra⁄cking, cell
adhesion and cell polarity [1]. Although there are at least 21
distinct Rho GTPase members, most studies have focused on
only three: Cdc42, Rac1 and RhoA. The ability of these
GTPases to regulate a myriad of cellular processes stems
from their interaction with multiple e¡ector proteins. These
interactions are generally GTP-dependent, whereby the inter-
action only occurs when these GTPases (Rho, Rac or Cdc42)
are bound to GTP [2,3]. Consequently, the ability of the Rho
GTPases to regulate or a¡ect signaling pathways is ultimately
determined by their nucleotide-bound state, which is con-
trolled by an intrinsic GTPase activity and by additional types
of regulatory proteins. These additional regulatory proteins
include guanine dissociation inhibitors, which stabilize either
the GDP- or GTP-bound state; guanine nucleotide exchange
factors (GEFs), proteins that promote the active GTP-bound
state by facilitating the exchange of GDP by GTP; and
GTPase activating proteins (GAPs) that inactivate the Rho
GTPases by promoting GTP hydrolysis [4,5]. This review fo-
cuses on one class of these regulatory proteins, the GAPs.
The ¢rst identi¢ed GAP protein, p50 rhoGAP, was puri¢ed
from human spleen extracts and found to stimulate the intrin-
sic GTPase activity of Rho, Rac and Cdc42 [6]. Initial cloning
of p50 rhoGAP revealed that it shared homology with two
other proteins, BCR and N-chimaerin, both of which also
stimulated hydrolysis of GTP bound to Rac and Cdc42 [7].
Subsequent molecular cloning and biochemical studies re-
vealed that a region of approximately 170 amino acids, des-
ignated the RhoGAP domain (also known as BH domain),
common to these proteins, was necessary and usually su⁄-
cient for the GAP activity [8]. Since then a large and diverse
collection of proteins has been found to contain sequences
encoding a similar domain, making each of these proteins a
potential candidate GAP for the Rho GTPases. The availabil-
ity of structural data from three di¡erent RhoGAP domains
[9^11] and complexes of one of these, p50 rhoGAP, with both
Cdc42 [12,13] and RhoA [14] provides important insights into
the mechanisms underlying RhoGAP-mediated GTP hydroly-
sis and provides a rational basis for making selected genetic
mutations. In particular, a conserved arginine residue, present
in most RhoGAP-containing proteins, is inserted into the ac-
tive site of all Rho GTPases and functions to stabilize a con-
formation needed for hydrolysis [12^14]. While mutational
analysis has con¢rmed the importance of this conserved argi-
nine residue [12,15], additional amino acids are required for
orientating the hydrolytic machinery of the Rho GTPases
[12,14] and are lacking in some inactive RhoGAP domain-
containing proteins such as p85K [10,11]. In this review, we
focus only on RhoGAP domains found in human proteins
and review what is known about these molecules including
possible mechanisms for their activation and summarize
some of the published speculations about the functional sig-
ni¢cance of the various RhoGAP domains. An in-depth anal-
ysis of 3D structures and details on the chemistry of catalysis
by RhoGAP proteins can be found in two recent reviews
[16,17].
2. Diverse human RhoGAP-containing proteins
We analyzed RhoGAP-containing proteins in the human
genome by searching current cDNA, expressed sequence
tags (ESTs) and genomic sequences at the National Center
for Biotechnology Information (NCBI) GenBank databases
using BLASTP and TBLASTN searches. In total, 53 distinct
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human cDNAs encoding potential RhoGAP domain-encod-
ing proteins were identi¢ed from publicly available databases
(Table 1). These results are in con£ict with the ¢rst draft of
the human genome sequence, which claimed 77 di¡erent hu-
man genes contain RhoGAP domains [18], many of which
were identi¢ed from duplicate database entries, from partial
sequences and as splice variants. Our analysis also revealed
that human RhoGAP-containing proteins are encoded
throughout the genome and rarely cluster in speci¢c chromo-
somal regions (Table 1).
Although the in vitro speci¢city of the GAP activity of
approximately half of the human proteins reviewed here is
known for RhoA, Rac1 and Cdc42 (Table 1), these results
may have limited physiological relevance because it has been
established that at least some of these molecules, for example
p190-A [19,20] and Myosin IXb [21], have di¡erent GAP
speci¢city in vitro and in vivo. Additional studies are also
needed to determine the speci¢city of these RhoGAPs towards
the less well-known members of the Rho GTPase family such
as RhoG and Wrch-1.
Table 1
Human RhoGAP-containing genes, chromosomal localization and GAP speci¢citya
Name and synonym(s) SwissProt TrEMBL PIR GenPept/RefSeq Chr Rho Rac Cdc42 Ref.
KIAA1501 Q9P227 A59434 BAA96025.1 16p11.2
KIAA1424; ArhGAP10 Q9P2C3 A59438 BAA92662.1 10p12
K-Chimaerin; N-chimaerin; chimerin-1 S08242 CAA35769.1 2q31 3 ++ 3 [7]
L-Chimaerin; RhoGAP3 A53764 AAA16836.1 7p15.3 3 ++ 3 [24] rat
p190-B, ARHGAP5; RhoGAP5 Q13017 B59431 NP_001164 14q12 ++ + + [28]
p190-A Q9NRY4 A40971 AAF80386.1 19q13.3 ++ 3 3 [20,29] rat
Oligophrenin-1 O60890 H59434 NP_002538 Xq12 ++ ++ ++ [36]
GRAF; oligophrenin-1 like protein Q9UNA1 F59430 NP_055886 5q31 ++ 3 ++ [33] chicken
GRAF-2 Q96S75 BAB61771.1 4q31.22 ++ 3 ++ [76]
KIAA0013 Q9Y3S6 A59431 NP_055598 15q24
KIAA0189 Q92502 B59430 NP_055540 Xq11.2
CAB42562; GT650 Q9Y3M8 H59432 NP_443083 13q12
DLC-1 (deleted in liver cancer), p122 O43199 G59435 NP_006085 8p22 ++ 3 ND [39,41] rat
ArhGAP6; RHG6; rhogap-x O43182 E59434 NP_038286 Xp22.3 ++ 3 3 [42] mouse
LOC118743; FLJ00194 XP_058340 10q24
KIAA1314; FLJ10312 Q9P2N2 E59436 BAA92552.1 18p11.3
CAC17688; C20orf95 Q9H1G7 H59433 CAC17688.2 20q11
MacGAP Q96S64 G59432 NP_277050 6q23.1
KIAA1391 Q9P2F6 C59436 BAA92629.1 11q23.2
RhoGAP8 Q9NSG0 B59436 CAB90248.1 22q13.3
p50 RhoGAP; Cdc42 RhoGAP Q07960 A49678 NP_004299 11 + + ++ [20,43,44]
RHG4; p115; C1 P98171 I38100 CAA55394.1 Xq28
srGAP-3; KIAA0411 G59434 CAC22407.1 3p25.3
srGAP-1; KIAA1304 Q9P2P2 G59436 BAA92542.1 12q14.1 + 3 ++ [46]
srGAP-2; KIAA0456; ARHGAP14 O75044 C59437 BAA32301.1 1q21.2
3BP-1 Q9Y3L3 T46916 22q13.1 3 ++ + [48]
KIAA0672 O75160 A59433 NP_055674 17p11.2
RICH-1; RhoGAP (NADRIN) Q96KS3 F59433 CAC37948.1 16p11.2 3 ++ ++ [49]
GMIP; LOC51291 Q9P107 D59435 NP_057657 19p11
PARG1 O15463 E59430 NP_004806 1p21.3 ++ + + [51]
HA-1; KIAA0233 Q92619 D59433 BAA13212.1 19p13.3
p85-K ; p85-alpha P27986 A38748 5q12 3 3 3 [8]
p85-L ; p85-beta O00459 H59435 NP_005018 19q13.2
INPP5B P32019 A41075 AAA79207.1 1p34
OCRL-1 G59431 NP_001578 Xq25^26
CHR 5 ORF Q9NYF5 B59433 NP_057687 5q31
KIAA1688 Q9C0H5 C59434 BAB21779.1 8q24.3
HYPO DKFZP56 Q9H0T6 A59430 NP_112595 4q21.3
KIAA0053 P42331 C59430 NP_055697 2p13.3
Myosin IXB; MYO9B A59256 NP_004136 1q13.1 ++ ND ND [21,57]
Myosin IXA Q9UNJ2 E59435 NP_008832 15q22
FLJ13511 O60432 E59437 AAC18917.1 19p13.3
ARAP1; CENTAURIN DELTA2 Q96L71 C59431 NP_056057 11q13.1 [58]
ARAP2; KIAA0580 Q9Y4E4 T00342 BAA25506.1 4p14
ARAP3; FLJ21065 Q8WWN8 E59431 CAC83946.1 5q31.3 [45]
KIAA1204; homolog of mouse
CdGAP
Q9ULL6 A59437 BAA86518.1 3q13
N-chimaerin homolog; LOC126397 O14560 T00705 AAB81198.1 19q13
MgcRacGAP; RacGAP-1; KIAA1478 Q9P2W2 D59430 NP_037409 12p13.2 3 ++ ++ [59]
RALBP1; RLIP76 Q15311 F59435 NP_006779 18p11.3 3 + ++ [61,62]
BCR P11274 TVHUBR NP_004318 22q11 3 ++ + [7,20]
ABR Q12979 A49307 NP_068781 17p13.3 3 ++ ++ [68,69]
ARHGAP9; RhoGAP9; MGC12959 Q96S74 JC7701 BAB56159.1 12q14 + ++ ++ [72]
ARHGAP12, RhoGAP-12; FLJ10971 Q9NT76 T46471 NP_060757 10p12
aThe order of the list is the same as given in the phylogenetic analysis (Fig. 1). Protein sequence IDs are included from the Swiss-Prot/
TrEMBL (http://www.ebi.ac.uk/swissprot/), PIR Protein Sequence (http://pir.georgetown.edu) and GenPept and RefSeq (http://www.ncbi.nlm.
nih.gov/LocusLink/) databases. GAP activity, if known, is as follows: ++, high activity; +, less activity; 3, no activity and ND, not deter-
mined. Unless otherwise indicated, the references are to the earliest in vitro and in vivo descriptions of GAP activity by human proteins.
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3. Evolutionary relationships of human RhoGAP-containing
proteins
In order to identify potential functional relationships
among the RhoGAP domains in these 53 human proteins,
we ¢rst generated a multiple sequence alignment of only their
RhoGAP domains (available at http://lombardi.georgetown.
edu/research/areas/growthregulation/rgalign2.htm). This align-
ment shows that the amino acids of all of these RhoGAP
domains are su⁄ciently homologous to justify concluding
that their 3D structures are also likely to be similar to the
RhoGAP domains found in p50 rhoGAP [9], p85 [10] and
GRAF [11]. Inspection of this pileup also showed that four
of these proteins, OCRL-1, INPP5B, CHR 5 ORF and
ARAP2, do not contain the conserved arginine residue sug-
gesting that these proteins do not have RhoGAP activity.
Using this alignment to de¢ne the N- and C-terminal ends
of the GAP domains, we determined the likely phylogenetic
relationship amongst these 53 RhoGAP domains (Fig. 1).
This phylogenetic analysis o¡ers evidence for frequent domain
duplication and for duplication of the entire genes containing
these domains. That is, when two RhoGAP domains are
closely related, we found that the entire proteins are more
closely related to each other than the entire protein having
RhoGAP domains from di¡erent families (Fig. 1). For exam-
ple, the similarity between the RhoGAP domains in Myosin
IXa and Myosin IXb was su⁄cient to predict that these two
proteins are more similar to one another than to any of the
other proteins analyzed. This analysis also showed that the
sequence homologies among the 53 di¡erent domains did not
strongly correlate with the speci¢c GAP activity towards
Cdc42, Rac and/or Rho. One possible explanation is that
several amino acids in these subdomains are involved in de-
termining RhoGAP speci¢city. Additional comparative stud-
ies are needed to determine which amino acid di¡erences are
involved in determining speci¢city and how these changes
a¡ect the 3D structures and/or interactions with the Rho
GTPases. Finally, the two RhoGAP-containing families that
presumably lack functional GAP activity, OCRL and the p85
subunits of phosphoinositide 3P-kinase families [8], appear
phylogenetically the most distant from the majority of the
GAPs (Fig. 1).
To further understand the evolution of the human Rho-
GAP-containing proteins, we compared human and Drosophi-
la melanogaster RhoGAP-containing proteins. Based on pre-
vious studies [22] and additional database searches, a total of
21 unique D. melanogaster RhoGAP-containing sequences
were detected. As in the human genome, genes encoding D.
melanogaster RhoGAP-containing proteins are widely dis-
persed in the genome (data not shown). Although six D. me-
lanogaster proteins are unique to this species, 15 have human
orthologs, including some involved in human diseases such as
BCR, GRAF, and OCRL-1 (Fig. 1). Interestingly, orthologs
for several human RhoGAP-containing families including
those for Myosin IX and srGAP were not found. The mere
existence of Drosophila and human orthologs suggests that
these conserved proteins may play important roles in these
organisms.
4. Overview of human RhoGAP-containing protein families
Since a previous review article on RhoGAP-containing pro-
teins by Lamarche and Hall in 1994 [4], the number of eu-
karyotic RhoGAP proteins identi¢ed and characterized has
increased immensely. Here we have focused on providing a
summary of what is known about human RhoGAP-contain-
ing proteins.
4.1. K-Chimaerin and L-chimaerin
K-Chimaerin and L-chimaerin both contain a phorbol ester-
C1 binding domain and a C-terminal RhoGAP domain (Fig.
2), while splice variants for these genes contain additional N-
terminal SH2 domains. Analysis of the RhoGAP domain of
K-chimaerins reveals GAP activity only for Rac [7]. The C1
sequences in L2-chimaerin, like those in protein kinase C
members, bind phorbol esters and regulate its accumulation
both at the plasma membrane and in the perinuclear compart-
ment [23]. While L-chimaerin and K-chimaerin show restricted
expression in the brain and testes, K2-chimaerin and L2-chi-
maerin splice variants are ubiquitously expressed [24,25]. In-
terestingly, L2-chimaerin mRNA expression is markedly
down-regulated in malignant gliomas compared to normal
brain and low grade astrocytoma [26].
Fig. 1. An unrooted phylogenetic tree of human RhoGAP-contain-
ing proteins. The tree was produced by amino acid sequence align-
ment of the 53 human RhoGAP-containing proteins (available at
http://bc.georgetown.edu/pb/RhoGAP) using the neighbor joining
method based on CLUSTAL W multiple sequence alignments. A
bar represents the number of substitution events (10 per 100 amino
acids). The Drosophila orthologs to the various human genes are in-
dicated in parentheses.
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4.2. p190-A and p190-B
p190-A was originally identi¢ed as a rat p120 RasGAP-
interacting protein [19]. In humans, two homologs, p190-A
[27] and p190-B [28], contain N-terminal GTPase, and C-ter-
minal RhoGAP domains (Fig. 2). While in vitro assays
demonstrated that p190-A has equal GAP activity for
Rho, Rac and Cdc42 [29], in vivo experiments with p190-A
demonstrated a preference for Rho [20]. Studies on p190 also
show that its RhoGAP activity is regulated by phosphoryla-
tion. Upon stimulation by growth factors or cell attachment,
tyrosine residues in the central portion of p190 are phosphor-
ylated by kinases such as Src [30]. This phosphorylation
causes a conformational change in the p190 molecule resulting
in the activation of its GAP activity, which decreases Rho
GTP levels and inhibits signaling to e¡ector proteins, leading
to a net loss of stress ¢bers. Mouse knockout studies indicate
that p190-A mediates Src-dependent adhesion signals in-
volved in neuritogenesis through its e¡ect on the intrinsic
GTPase activity of Rho and are consistent with it being the
major tyrosine phosphorylated protein in the brain [31].
These results are also supported by genetic analysis in Droso-
phila showing that a p190 homolog regulates axon branch
stability [22]. Interestingly, knockout of the mouse p190-B
homolog dramatically decreases the size of mice, an e¡ect
that appears to be mediated through a transcription factor,
CREB [32].
4.3. GRAF, GRAF-2 and Oligophrenin-1
The three human members of this family, GRAF, GRAF-2
and Oligophrenin-1, all contain a PH domain and a RhoGAP
domain (Fig. 2). In addition, GRAF and GRAF-2 contain
C-terminal SH3 domains. The ¢rst known member of this
family, designated GRAF, was originally identi¢ed as a chick-
en cDNA encoding a protein that speci¢cally interacted with
focal adhesion kinase and possessed GAP activity for Rho
and Cdc42 in vitro [33]. More recently, human GRAF was
detected as a fusion partner with the mixed-lineage leukemia
(MLL) gene and inactivation of both alleles was detected in
several patients with myelodysplastic syndrome [34]. Another
family member, human GRAF-2, was identi¢ed in a yeast
two-hybrid screen as being able to interact with the Rho ef-
fector protein, PKN-L (a novel isoform of PKN; also known
as PRK) [35]. In vitro studies with the GAP domain of
GRAF-2 reveal that it is active towards Cdc42 and Rho,
but not Rac. Current thinking suggests that these molecules
may act as adapters to coordinate Rho activity with kinase
signaling pathways.
Oligophrenin-1 was ¢rst identi¢ed as a gene deleted in X-
linked mental retardation [36]. Oligophrenin-1 has equal GAP
activity for all three Rho GTPases. A high level of expression
of Oligophrenin-1 in the fetal brain suggests that this protein
may function in regulating Rho GTPases during neuritogen-
esis. In addition to its role in normal brain development, gene
array studies indicate that Oligophrenin-1 is overexpressed in
some cancers including colon cancer [37] and in glial tumors
[38].
4.4. DLC-1
DLC-1, the human analog of the rat p122 protein [39], is
frequently deleted in hepatocellular carcinoma [40]. The Rho-
GAP domain of DLC-1 is located in its C-terminus (Fig. 2)
and studies with the rat homolog reveal RhoGAP activity
towards Rho in vitro and in vivo [39,41]. While this molecule
can also interact and activate phospholipase C N1 activity,
transfection studies indicate that the ability of p122 to induce
cell detachment is only due to its RhoGAP activity [41].
Fig. 2. Schematic representation of selected human RhoGAP-containing proteins. Representative members of each cluster are shown. Domain
name abbreviations: C1, cysteine-rich phorbol ester binding; C2, calcium-dependent lipid binding; CC, coiled-coil; DH, Dbl homology; EH,
Eps15 homology; FCH, Fes/CIP4 homology; IQ, calmodulin binding motif; P, proline-rich; PH, pleckstrin homology; RBD, Ras binding do-
main; RhoGAP, Rho GTPase activating protein; SH3, Src homology 3; Sec14, sec14-like.
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4.5. ArhGAP6
ArhGAP6 contains a central RhoGAP domain (Fig. 2) and
several potential SH3 domain binding sequences [42]. Arh-
GAP6 was originally identi¢ed as a potential cause of micro-
ophthalmia with linear skin defects syndrome (MLS) charac-
terized by eye, skin and central nervous system malformations
[42]. Although the ArhGAP6 gene is commonly deleted in
MLS, additional studies using transgenic mice do not support
a role for a mutant ArhGAP6 gene as being causative in
MLS. While the GAP domain of ArhGAP6 has activity for
RhoA-GTP but not for GTP bound to Rac1 or Cdc42, trans-
fection studies suggest that it can also regulate actin changes
independent of the RhoGAP domain [42].
4.6. p50 rhoGAP
p50 rhoGAP, the ¢rst RhoGAP protein identi¢ed [43,44], is
expressed ubiquitously and is the smallest member of the
RhoGAP family (499 amino acids). p50 rhoGAP contains
an N-terminal Sec14 domain and a C-terminal RhoGAP do-
main (Fig. 2). In vitro and in vivo studies show that p50
rhoGAP preferentially binds Cdc42 over Rho and Rac
[20,43,44]. Phospholipid a⁄nity chromatography studies
have recently added p50 rhoGAP to the list of proteins that
can bind phosphatidylinositol 3,4,5-trisphosphate (PtdIns-
(3,4,5)P3) [45]. The interaction of p50 rhoGAP with
PtdIns(3,4,5)P3 likely involves the Sec14 domain [45], a do-
main originally found in the yeast phosphoinositol transfer
protein Sec14p. Although not yet tested, p50 rhoGAP inter-
actions with PtdIns(3,4,5)P3 might result in its recruitment to
the plasma membrane and/or conformational changes that
regulate its GAP activity.
4.7. srGAP-1, srGAP-2 and srGAP-3
The srGAP family contains an N-terminal FCH domain, a
central RhoGAP domain and a C-terminal SH3 domain (Fig.
2). The three members, srGAP-1, srGAP-2 and srGAP-3, are
all binding partners for the intracellular tail of the Round-
about receptor (Robo), a receptor that binds the Slit secreted
protein and mediates signaling pathways involved in cellular
repulsion [46]. While srGAP-2 protein is ubiquitously ex-
pressed, srGAP-1 is highly expressed in the lung (less so in
the brain, kidney and testes) and srGAP-3 is highly expressed
in brain, lung and spleen. Mapping experiments showed that a
proline-rich sequence (PPPPVPPP) in the Robo receptor in-
tracellular tail interacts with the SH3 domain of the srGAPs
[46]. Based on these interactions, Slit ligand binding to Robo
is thought to induce a conformational change in the intra-
cellular tail of Robo, exposing a buried SH3 binding se-
quence. srGAPs contain SH3 domains that interact with the
now exposed proline-rich SH3 binding site in Robo. This
interaction then activates the RhoGAP activity of srGAPs
and causes a local down-regulation of Cdc42 [46]. The result-
ing decrease in Cdc42 GTP levels leads to a localized loss of
actin polymerization and actin-associated structures including
¢lopodia and lamellipodia. A localized loss of the ability to
increase or maintain a normal level of actin polymerization
may explain the inability of certain cells to move in the direc-
tion of the Slit ligand gradient [46].
4.8. 3BP-1
3BP-1 was originally identi¢ed by far Western screening as
a protein capable of interacting with the SH3 domain of c-Abl
[47]. 3BP-1 contains a central RhoGAP domain and a proline-
rich SH3 binding domain in its C-terminus (Fig. 2). In vitro
studies have shown that 3BP-1 has GAP activity towards Rac,
but not for Rho or Cdc42 [48]. 3BP-1 may normally function
to limit Rac signaling, since microinjection of 3BP-1 into se-
rum-starved ¢broblasts inhibited PDGF-stimulated Rac-medi-
ated membrane ru¥ing [48].
4.9. Rich-1
Rich-1 was identi¢ed in a yeast two-hybrid screen using
CIP4, a Cdc42 e¡ector protein, as bait [49]. Rich-1 contains
an N-terminal endophilin homology (EH) domain, a Rho-
GAP domain and several C-terminal proline-rich regions
(Fig. 2). Domain mapping studies show that the proline-rich
region of Rich-1 interacts with the SH3 domain of CIP4.
Although not yet tested, the EH domain in CIP4, as the
EH domain in endophilin [50], may function in tubulovesicu-
lar membrane tra⁄cking by binding and evaginating lipid
bilayers at the clathrin-coated pit. In vitro experiments show
that Rich-1 has GAP activity for Cdc42 and Rac but not for
RhoA [49]. These in vitro results are consistent with the
known in vivo e¡ects of Rich-1, where overexpression inhibits
Rac-mediated membrane ru¥ing, but has no e¡ect on Rho-
induced stress ¢ber formation [49].
4.10. PARG1
PARG1 contains a RhoGAP domain and a cysteine-rich
domain related to a phorbol ester/diacylglycerol binding do-
main (Fig. 2). PARG1 was identi¢ed by a⁄nity chromatog-
raphy as a protein whose C-terminal sequence DYQCTIL
interacts with the fourth PDZ domain of the protein tyrosine
phosphatase PTPL1. Although the RhoGAP domain of
PARG1 shows preferential GAP activity towards Rho in
vivo, little else is known about the normal function of this
protein [51].
4.11. p85-K and p85-L
p85-K and p85-L subunits are highly homologous proteins
characterized by an N-terminal SH3 domain, two SH2 do-
mains and a region with only partial homology to the con-
sensus RhoGAP domain (Fig. 2). The p85-K and p85-L pro-
teins are known to function as regulatory subunits for the
110 kDa catalytic subunit of phosphatidylinositol 3-kinase
[52,53], which phosphorylates the inositol ring at the 3-posi-
tion. Unlike other RhoGAP-containing proteins, p85-K does
not have catalytic activity [8]. Nevertheless, the RhoGAP do-
mains in these subunits may have functional signi¢cance, as
p85-K can interact with GTP-bound Cdc42 and Rac in vitro
and co-immunoprecipitates with Cdc42 in a GTP-dependent
fashion [54]. Thus, p85 subunits may act as adapter proteins
to localize phosphatidylinositol 3-kinase activity to sites of
Cdc42 activation.
4.12. OCRL-1 and INPP5B
OCRL-1 was originally discovered because mutations in
this gene are responsible for Lowe’s Syndrome (also known
as oculocerebrorenal syndrome). This syndrome is character-
ized by eye and renal abnormalities and severe mental retar-
dation [55]. OCRL-1 and a related protein, INPP5B (type II
Ins-polyphosphate 5-phosphatase), have a central inositol po-
lyphosphate 5-phosphatase catalytic domain and a C-terminal
RhoGAP domain (Fig. 2). OCRL-1 appears to normally func-
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tion in protein tra⁄cking [56]. Although the RhoGAP speci-
¢city of OCRL-1 and INPP5B has not been reported, both
proteins are expected to be inactive because they contain a
glutamine instead of the conserved arginine in the active site.
4.13. Myosin IXa and Myosin IXb
Myosins are highly diverse proteins consisting of at least 14
di¡erent classes. The Myosin IX class contain a typical my-
osin-like head domain, an actin binding region, IQ-calmodu-
lin binding repeats, a protein kinase C regulatory domain and
a RhoGAP domain in the C-terminus (Fig. 2). To date only
human Myosin IXb has been characterized in vitro and in
vivo for GAP activity. Myosin IXb is highly expressed in
peripheral blood lymphocytes [21,57] and like other myosins,
has active motor activity that is inhibited by calcium [57]. In
vitro analysis of the GAP activity in Myosin IXb revealed
that it is speci¢c for Rho. It has been postulated that this
GAP activity may be involved in transiently inhibiting Rho
activity during the early stages of cell spreading.
4.14. ARAP1, ARAP2, and ARAP3
The ARAP subfamily is a recently discovered subclass of
Arf GAP-containing proteins [45,58]. All three human ARAP
proteins are characterized by having a common set of do-
mains, which include ¢ve PH domains, an Arf GAP domain
and a RhoGAP domain (Fig. 2). The PH domains in ARAP1
[58] and ARAP3 [45] function to speci¢cally bind
PtdIns(3,4,5)P3 thereby increase Arf GAP activity. In vitro
studies showed that recombinant ARAP1 [58] and ARAP3
[45] have equal GAP activity toward Rho, Rac and Cdc42.
Unlike the Arf GAP activity of ARAP1 and ARAP3, the
RhoGAP activity was neither stimulated nor inhibited by
PtdIns(3,4,5)P3 binding [45,58]. Interestingly, one of the
ARAP members, ARAP2, lacks the catalytic arginine in the
active site and thus may not have RhoGAP activity. Although
the exact function of these molecules is not known, ARAPs,
with phosphoinositide binding and Arf GAP and RhoGAP
activities, may function normally to coordinate protein traf-
¢cking with actin cytoskeletal changes.
4.15. MgcRacGAP
MgcRacGAP contains an N-terminal ERM domain, a cen-
tral protein kinase C-like cysteine-rich motif and a C-terminal
RhoGAP domain (Fig. 2). MgcRacGAP shows equal GAP
activity towards Rac1 and Cdc42 and is 30 times less active
towards RhoA [59]. MgcRacGAP is mainly expressed in male
germ cells and is implicated in mitotic spindle formation. In-
terestingly, an N-terminal coiled-coil-like domain of MgcRac-
GAP directly binds microtubules and is required for localiza-
tion to the central spindle and midbody during late M phase
[60].
4.16. RALBP1
RALBP1, also known as RLIP76, contains an N-terminal
K-helical region, a central RhoGAP domain, and a C-terminal
RAL GTPase binding region (Fig. 2). In vitro RhoGAP as-
says revealed activity towards Cdc42 and less towards Rac1
but none for RhoA [61,62]. RALBP1 can also interact with
Reps1, an Eps homology domain-containing protein, which is
tyrosine phosphorylated in response to epidermal growth fac-
tor (EGF) stimulation of cells and then binds to the SH3
domains of the adapter proteins Crk and Grb2 [63]. Since
the Ral GTPase is known to be involved in protein tra⁄cking,
the potential protein interactions involving RALBP1 could
possibly coordinate cellular signaling between activated EGF
receptors and other small GTPases such as Ras and Cdc42.
Other studies with RALBP1 indicate it also may have a role
in multidrug resistance because it appears to be active in
transmembrane transport of glutathione conjugates and xeno-
biotics [64].
4.17. BCR and ABR
BCR was originally discovered as a human gene on chro-
mosome 22 that is often translocated along with the c-Abl
tyrosine kinase on chromosome 9 [65]. This translocation
event results in the production of BCR-cAbl tyrosine kinase
fusion proteins present in many patients with chronic myeloid
leukemia or acute lymphoblastic leukemia. The BCR protein
contains multiple domains including an N-terminal kinase
domain, a Dbl domain, a PH domain and a C-terminal Rho-
GAP domain (Fig. 2). In vitro and in vivo data suggest that
BCR has GAP activity primarily for Rac [7,20]. Since the Dbl
region of BCR has the most RhoGEF activity for Cdc42, and
less activity towards Rac and Rho, it has been proposed that
BCR, having both GAP and GEF activities, may function to
temporally regulate the activity of these GTPases [66]. Gene
knockout studies in mice suggest an important role for BCR
in down-regulating Rac-mediated NADPH oxidase activity in
neutrophils [67]. A related smaller protein, ABR, is structur-
ally similar to BCR but lacks the N-terminal kinase domain
and has GAP activity for both Rac and Cdc42 [68,69]. While
knockout mice for ABR do not show an obvious phenotype,
double knockouts for ABR and BCR exhibit functional and
structural abnormalities of glial cells and show vestibular dys-
genesis [70,71].
4.18. ARHGAP9 and ARHGAP12
The ARHGAP9 protein contains an SH3 domain, a PH
domain and a WW domain along with the RhoGAP domain
(Fig. 2). In vitro studies indicate that ARHGAP9 has GAP
activity toward Rac1 and Cdc42, but less towards Rho [72].
Expression studies reveal high levels of ARHGAP9 expression
in hematopoietic tissues including cell lines from B-cell leuke-
mias, T-cell leukemias, and myeloid or Hodgkin lymphomas.
Transfection analysis suggests that ARHGAP9 may play a
role in the regulation of cellular adhesion of hematopoietic
cells to extracellular matrix molecules. ARHGAP12, a protein
with a domain structure similar to ARHGAP9 but containing
two WW domains, is expressed ubiquitously in a wide range
of normal tissues and tumor cell lines and is expressed
strongly in breast carcinomas [73]. The biological function
and speci¢city of the RhoGAP domain in ARHGAP9 is not
known. Furthermore, the SH3 and WW domains, both of
which mediate protein^protein interactions with unique pro-
line-rich sequences in target proteins, may regulate the GAP
activity of both ARHGAP9 and ARHGAP12 proteins.
5. Conclusions
The 53 human RhoGAP domain-containing proteins are
the largest known group of Rho GTPase regulators and sig-
ni¢cantly outnumber the 21 Rho GTPases they presumably
regulate. This excess of GAP proteins probably indicates com-
plex regulation of the Rho GTPases and is consistent with the
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existence of almost as many (48) human Dbl domain-contain-
ing Rho GEFs [74] that act antagonistically to the RhoGAP
proteins by activating the Rho GTPases. While some Rho-
GAP-containing proteins are involved in several human genet-
ic diseases and/or show altered levels of expression in certain
kinds of cancers, the normal functions of most of the domains
in these molecules are not known. A major experimental lim-
itation to increasing our understanding of these proteins is
that the most frequently used techniques, transfection and
microinjection, may not provide reliable information about
possible normal functions because introducing excess amounts
of these kinds of proteins into cells usually results in consti-
tutive GAP activity. Since unregulated GAP activity dramat-
ically inhibits the Rho GTPases and typically disrupts normal
actin dynamics, making correct inferences about the normal
biological function of the RhoGAPs may be di⁄cult or im-
possible with these techniques. Gene knockouts in mice, such
as those for BCR [67], p190-A [22], and p190-B [32], may
more reliably reveal the normal in vivo function of RhoGAP
domain-containing proteins. Targeted knockins, where only
the GAP domain is mutated, may also be helpful to determine
the functional signi¢cance of GAP activity. Finally, studies
using RNAi experiments, a rapid method to inhibit gene ex-
pression, may also help elucidate the in vivo function of Rho-
GAP proteins. This method was used recently to examine
RhoGEF function [75]. Although current knowledge about
the in vivo biological function of most RhoGAP-containing
proteins is still rudimentary, we understand even less about
how the diverse GAP activities are controlled at the molecular
level, including whether these molecules are also involved in
integrating multiple signals and if so, how they integrate these
signals.
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